This company listing is no longer active
TFF Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Craig Jalbert
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?
Apr 10
Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?
Sep 27TFF Pharma: The Potential Is Still Very Much Present
Aug 29TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways
Aug 09TFF Pharmaceuticals expands R&D operations with new Austin facility
Jul 14TFF Pharmaceuticals: A Highly Attractive Basket Of Options
May 23CEO
Craig Jalbert (62 yo)
less than a year
Tenure
Mr. Craig R. Jalbert serve as a CEO, President, Chief Financial Officer, Treasurer and Secretary and sole member of the board since November 2024 at TFF Pharmaceuticals, Inc. He is President, Treasurer, CS...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | less than a year | no data | no data | |
| Chairman of the Scientific Advisory Board and Senior Research & Development Advisor | 1.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data |
3.3yrs
Average Tenure
Experienced Board: TFFP's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/15 22:08 |
| End of Day Share Price | 2024/12/12 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TFF Pharmaceuticals, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |